Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China.
First School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
Medicine (Baltimore). 2024 May 10;103(19):e38110. doi: 10.1097/MD.0000000000038110.
The Philadelphia chromosome (Ph) is seen in most patients with chronic myeloid leukemia and some patients with acute lymphoblastic leukemia. However, Ph-positive acute myeloid leukemia (Ph + AML) is a rare entity with a poor prognosis and a short median survival period. To date, there have been few clinical reports on this disease. And the treatment regimen of this disease has not been uniformly determined.
We report a case of a Ph + AML. A 32-year-old male who was admitted to our hospital with weakness for 2 months.
Philadelphia chromosome-positive acute myeloid leukemia.
The patient achieved complete remission by the administration of a tyrosine kinase inhibitor, combined with low-intensity chemotherapy and a B-cell lymphoma 2 inhibitor. Then, allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his sister was successfully performed.
The patient has been in a continuous remission state for 6 months after transplantation.
We reported a rare Ph + AML case, successfully treated with allo-HSCT. This case provided strong support for treating Ph + AML with allo-HSCT.
费城染色体（Ph）见于大多数慢性髓性白血病患者和一些急性淋巴细胞白血病患者。然而，Ph 阳性急性髓系白血病（Ph+AML）是一种罕见的实体，预后不良，中位生存期短。迄今为止，关于这种疾病的临床报道很少。而且，这种疾病的治疗方案尚未统一确定。
我们报告了一例 Ph+AML。一名 32 岁男性，因乏力 2 个月入住我院。
费城染色体阳性急性髓系白血病。
该患者通过酪氨酸激酶抑制剂联合低强度化疗和 B 细胞淋巴瘤 2 抑制剂达到完全缓解。然后，他的姐姐成功地进行了异基因造血干细胞移植（allo-HSCT）。
移植后 6 个月，患者持续缓解。
我们报告了一例罕见的 Ph+AML 病例，成功地接受了 allo-HSCT 治疗。该病例为 allo-HSCT 治疗 Ph+AML 提供了有力支持。
